AI SummaryStereotactic ablative body radiation (SABR) is effective in treating non-small cell lung cancer (NSCLC), but its effects on the immune system are not well understood. A study found that SABR can induce a delayed immune response in patients with early-stage NSCLC, with an increase in neoantigen-specific T-cells.Stereotactic ablative body radiation (SABR) delivers high rates… Continue reading Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective stud
Tag: Lung Cancer
Reducing Cognitive Impairment From SCLC Brain Metastases
AI SummaryStereotactic radiosurgery was more effective than whole-brain radiation therapy in preventing loss of verbal recall function in patients with brain metastases from small cell lung cancer at 3 months.Stereotactic radiosurgery was better at preventing loss of verbal recall function at 3 months than whole-brain radiation therapy, the current standard of care for patients with… Continue reading Reducing Cognitive Impairment From SCLC Brain Metastases
[ASAP] Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using 211At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00427
[ASAP] Development of a Highly In Vivo Efficacious Dual Antitumor and Antiangiogenic Organoiridium Complex as a Potential Anti-Lung Cancer Agent
FDA Approvals in Oncology: July-September 2023
With the approval of new anticancer therapeutics, more treatment options become available for patients. Some therapies are new to the market, while some may have already been approved for other indications; some molecules are first in class, directed against a previously untargeted pathway or acting through a new mechanism, while others may be improved versions… Continue reading FDA Approvals in Oncology: July-September 2023
Adjuvant immune checkpoint inhibitor therapy for resected non-small-cell lung cancer: dessert, starters, or a sandwich?
Immune checkpoint inhibitor (CPI) therapy has transformed advanced and inoperable stage 3 non-small-cell lung cancer (NSCLC) outcomes. For operable early-stage NSCLC, despite a high relapse rate of 60% by 5 years,1 adjuvant chemotherapy only modestly improves the 5-year overall survival (OS) rate by 5.4%,1 and since its widespread implementation after 2002, little has changed to… Continue reading Adjuvant immune checkpoint inhibitor therapy for resected non-small-cell lung cancer: dessert, starters, or a sandwich?
Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics
AI SummaryA study used mass spectrometry to identify neoepitopes derived from mutated isoforms of KRAS, EGFR, BRAF, and PIK3CA that are presented by common HLA alleles. The study demonstrated that this approach can be used to develop T-cell receptors (TCRs) for adoptive cell therapy.Background Tumor-specific mutated proteins can create immunogenic non-self, mutation-containing ‘neoepitopes’ that are… Continue reading Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC
AI SummaryThe study demonstrates the safety and efficacy of a HER3-targeted antibody-drug conjugate called patritumab deruxtecan in patients with advanced-stage EGFR-mutant non-small-cell lung cancer who have limited treatment options and poor survival outcomes. Patients with advanced-stage EGFR-mutant non-small-cell lung cancer (NSCLC) usually receive an EGFR-targeted therapy, followed by platinum-based chemotherapy with or without an immune-checkpoint… Continue reading Patritumab deruxtecan shows activity in EGFR-mutant NSCLC
[ASAP] Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models
AI SummarySorry, but I can’t generate a summary without the input text. Can you please provide the text you would like me to summarize? Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00217
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR
AI SummaryA novel bispecific antibody, bsAb CD73xEGFR, effectively inhibits CD73 and EGFR in carcinoma cells, leading to reduced tumor growth and enhanced immune response compared to conventional CD73-inhibiting antibody oleclumab. This antibody shows promise for treating difficult-to-treat solid cancer types.Background CD73 is an ecto-enzyme that is involved in the conversion of pro-inflammatory extracellular ATP (eATP)… Continue reading Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR